{"id":67981,"date":"2026-06-11T14:49:46","date_gmt":"2026-06-11T06:49:46","guid":{"rendered":"https:\/\/flcube.com\/?p=67981"},"modified":"2026-06-11T14:49:47","modified_gmt":"2026-06-11T06:49:47","slug":"bio-thera-solutions-secures-singapore-approval-for-bat2206-biosimilar-to-jjs-stelara-expanding-access-across-multiple-autoimmune-indications","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67981","title":{"rendered":"Bio-Thera Solutions Secures Singapore Approval for BAT2206, Biosimilar to J&amp;J&#8217;s Stelara, Expanding Access Across Multiple Autoimmune Indications"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Bio-Thera Solutions Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688177:SHA\">SHA: 688177<\/a>) announced it has received <strong>marketing approval from Singapore&#8217;s Health Sciences Authority<\/strong> for <strong>BAT2206<\/strong>, a <strong>biosimilar<\/strong> to <strong>Johnson &amp; Johnson&#8217;s<\/strong> blockbuster autoimmune therapy <strong>Stelara (ustekinumab)<\/strong>, significantly broadening treatment access across multiple inflammatory conditions in both adult and pediatric populations.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Bio-Thera Solutions Ltd. (SHA: 688177)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>BAT2206 (ustekinumab biosimilar)<\/td><\/tr><tr><td><strong>Reference Product<\/strong><\/td><td>Stelara (J&amp;J\/Janssen)<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>Singapore Health Sciences Authority<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>11 Jun 2026<\/td><\/tr><tr><td><strong>Indications Approved<\/strong><\/td><td>Adult: Moderate-to-severe plaque psoriasis (PsO), active psoriatic arthritis (PsA), moderate-to-severe active Crohn&#8217;s disease (CD)<br>Pediatric: Moderate-to-severe plaque psoriasis (PsO), moderate-to-severe active Crohn&#8217;s disease (CD)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Fully human monoclonal antibody (biosimilar to ustekinumab)<\/li>\n\n\n\n<li><strong>Target:<\/strong> p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23)<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> High-affinity binding to p40 subunit blocks interaction with cell surface receptors, disrupting IL-12- and IL-23-mediated signaling pathways critical in inflammatory and immune responses<\/li>\n\n\n\n<li><strong>Therapeutic Class:<\/strong> Immunomodulator targeting key cytokines in autoimmune disease pathogenesis<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">BAT2206 represents Bio-Thera&#8217;s strategic entry into the high-value biologics market for chronic inflammatory diseases. By targeting the shared p40 subunit of IL-12 and IL-23\u2014cytokines that drive inflammation in multiple autoimmune conditions\u2014the biosimilar offers a comprehensive therapeutic approach across diverse patient populations.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-commercial-strategy\" class=\"wp-block-heading\">Market Impact &amp; Commercial Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Singapore Market Opportunity:<\/strong> Estimated 15,000-20,000 patients across approved indications with limited biosimilar competition in the IL-12\/23 inhibitor class<\/li>\n\n\n\n<li><strong>Pricing Advantage:<\/strong> Expected to be priced 25-35% below originator Stelara, aligning with typical biosimilar discount ranges in developed Asian markets<\/li>\n\n\n\n<li><strong>Global Expansion:<\/strong> Singapore approval serves as a regulatory gateway for broader ASEAN market access, with submissions planned in Malaysia, Thailand, and Indonesia by Q4 2026<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> First ustekinumab biosimilar approved in Singapore; competes against J&amp;J&#8217;s originator and emerging biosimilars from Celltrion and Samsung Bioepis in other markets<\/li>\n\n\n\n<li><strong>Revenue Projection:<\/strong> Bio-Thera forecasts SGD 45-60 million (USD 33-44 million) in annual peak sales across Southeast Asia, representing approximately 8-12% of the company&#8217;s projected 2028 revenue<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The approval positions Bio-Thera as a leading Chinese biopharmaceutical exporter in the global biosimilars space, leveraging Singapore&#8217;s reputation as a regulatory benchmark for the broader Asia-Pacific region.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial projections. Actual results may differ due to competitive dynamics, pricing pressures, and regulatory developments in target markets.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688177_20260611_7XWW.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688177_20260611_7XWW.\"><\/object><a id=\"wp-block-file--media-99c8c576-28bc-4b5e-bd46-6aa17d52ef7b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688177_20260611_7XWW.pdf\">688177_20260611_7XWW<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688177_20260611_7XWW.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-99c8c576-28bc-4b5e-bd46-6aa17d52ef7b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Bio-Thera Solutions Ltd. (SHA: 688177) announced it has received marketing approval from Singapore&#8217;s Health Sciences&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[65,289,43,149,15,1055],"class_list":["post-67981","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-bio-thera-solutions","tag-biosimilars","tag-johnson-johnson","tag-product-approvals","tag-sha-688177"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bio-Thera Solutions Secures Singapore Approval for BAT2206, Biosimilar to J&amp;J&#039;s Stelara, Expanding Access Across Multiple Autoimmune Indications - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bio-Thera Solutions Ltd. (SHA: 688177) announced it has received marketing approval from Singapore&#039;s Health Sciences Authority for BAT2206, a biosimilar to Johnson &amp; Johnson&#039;s blockbuster autoimmune therapy Stelara (ustekinumab), significantly broadening treatment access across multiple inflammatory conditions in both adult and pediatric populations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67981\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bio-Thera Solutions Secures Singapore Approval for BAT2206, Biosimilar to J&amp;J&#039;s Stelara, Expanding Access Across Multiple Autoimmune Indications\" \/>\n<meta property=\"og:description\" content=\"Bio-Thera Solutions Ltd. (SHA: 688177) announced it has received marketing approval from Singapore&#039;s Health Sciences Authority for BAT2206, a biosimilar to Johnson &amp; Johnson&#039;s blockbuster autoimmune therapy Stelara (ustekinumab), significantly broadening treatment access across multiple inflammatory conditions in both adult and pediatric populations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67981\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-11T06:49:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-11T06:49:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67981#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67981\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bio-Thera Solutions Secures Singapore Approval for BAT2206, Biosimilar to J&amp;J&#8217;s Stelara, Expanding Access Across Multiple Autoimmune Indications\",\"datePublished\":\"2026-06-11T06:49:46+00:00\",\"dateModified\":\"2026-06-11T06:49:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67981\"},\"wordCount\":410,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Bio-Thera Solutions\",\"Biosimilars\",\"Johnson &amp; Johnson\",\"Product approvals\",\"SHA: 688177\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67981#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67981\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67981\",\"name\":\"Bio-Thera Solutions Secures Singapore Approval for BAT2206, Biosimilar to J&amp;J's Stelara, Expanding Access Across Multiple Autoimmune Indications - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-11T06:49:46+00:00\",\"dateModified\":\"2026-06-11T06:49:47+00:00\",\"description\":\"Bio-Thera Solutions Ltd. (SHA: 688177) announced it has received marketing approval from Singapore's Health Sciences Authority for BAT2206, a biosimilar to Johnson & Johnson's blockbuster autoimmune therapy Stelara (ustekinumab), significantly broadening treatment access across multiple inflammatory conditions in both adult and pediatric populations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67981#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67981\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67981#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bio-Thera Solutions Secures Singapore Approval for BAT2206, Biosimilar to J&amp;J&#8217;s Stelara, Expanding Access Across Multiple Autoimmune Indications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bio-Thera Solutions Secures Singapore Approval for BAT2206, Biosimilar to J&amp;J's Stelara, Expanding Access Across Multiple Autoimmune Indications - Insight, China&#039;s Pharmaceutical Industry","description":"Bio-Thera Solutions Ltd. (SHA: 688177) announced it has received marketing approval from Singapore's Health Sciences Authority for BAT2206, a biosimilar to Johnson & Johnson's blockbuster autoimmune therapy Stelara (ustekinumab), significantly broadening treatment access across multiple inflammatory conditions in both adult and pediatric populations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67981","og_locale":"en_US","og_type":"article","og_title":"Bio-Thera Solutions Secures Singapore Approval for BAT2206, Biosimilar to J&amp;J's Stelara, Expanding Access Across Multiple Autoimmune Indications","og_description":"Bio-Thera Solutions Ltd. (SHA: 688177) announced it has received marketing approval from Singapore's Health Sciences Authority for BAT2206, a biosimilar to Johnson & Johnson's blockbuster autoimmune therapy Stelara (ustekinumab), significantly broadening treatment access across multiple inflammatory conditions in both adult and pediatric populations.","og_url":"https:\/\/flcube.com\/?p=67981","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-11T06:49:46+00:00","article_modified_time":"2026-06-11T06:49:47+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67981#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67981"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bio-Thera Solutions Secures Singapore Approval for BAT2206, Biosimilar to J&amp;J&#8217;s Stelara, Expanding Access Across Multiple Autoimmune Indications","datePublished":"2026-06-11T06:49:46+00:00","dateModified":"2026-06-11T06:49:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67981"},"wordCount":410,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Bio-Thera Solutions","Biosimilars","Johnson &amp; Johnson","Product approvals","SHA: 688177"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67981#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67981","url":"https:\/\/flcube.com\/?p=67981","name":"Bio-Thera Solutions Secures Singapore Approval for BAT2206, Biosimilar to J&amp;J's Stelara, Expanding Access Across Multiple Autoimmune Indications - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-11T06:49:46+00:00","dateModified":"2026-06-11T06:49:47+00:00","description":"Bio-Thera Solutions Ltd. (SHA: 688177) announced it has received marketing approval from Singapore's Health Sciences Authority for BAT2206, a biosimilar to Johnson & Johnson's blockbuster autoimmune therapy Stelara (ustekinumab), significantly broadening treatment access across multiple inflammatory conditions in both adult and pediatric populations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67981#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67981"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67981#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bio-Thera Solutions Secures Singapore Approval for BAT2206, Biosimilar to J&amp;J&#8217;s Stelara, Expanding Access Across Multiple Autoimmune Indications"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67981"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67981\/revisions"}],"predecessor-version":[{"id":67983,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67981\/revisions\/67983"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}